Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34)

被引:61
作者
Hirano, T
Burr, DB [1 ]
Cain, RL
Hock, JM
机构
[1] Indiana Univ, Sch Med, Dept Anat & Cell Biol & Orthoped Surg, Indianapolis, IN 46202 USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
PTH; mechanical strength; cross-sectional moment of inertia; cortical porosity; osteoporosis;
D O I
10.1007/s002230010091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to determine if the increased cortical bone porosity induced by intermittently administered parathyroid hormone (PTH) reduces bone strength significantly. Mature ovary-intact New Zealand white rabbits were treated with once daily injections of vehicle, or PTH(1-34), LY333334, at 10 or 40 mu g/kg/day for 140 days. Geometry of the femoral midshaft was measured to evaluate changes in the cross-sectional moment of inertia (CSMI). Cortical porosity was measured in the midshaft of the tibia by dividing cortical area into three zones based on equal divisions of cortical diameter: near endocortical (Zone I), near intermediate (Zone II), and near periosteal (Zone III) regions. Total cortical porosity significantly increased after PTH treatment from 1.4% in the controls to 6.3% in the higher dose group, but the location of the new porosities was not randomly distributed. In the controls, porosity of Zones I and II (both 1.7%) was almost twice as much as that of Zone III (0.9%). In the lower dose group, cortical porosity of Zone I (5.5%) and II (1.8%) was greater than in Zone III (0.9%), but these differences were not statistically significant. ir; the higher dose group, cortical porosity of Zone I (11.5%) and II (6.1%) significantly increased compared with Zone III (1.4%) (P < 0.0005). Histomorphometric measurements showed that bone formation rate on both periosteal and endocortical surfaces increased, resulting in increased bone area and cortical area in the higher dose group. A model was developed to evaluate the effect of the changes in geometry and porosity on CSMI in the different zones, This simulation model indicated that CSMI in the higher dose group was significantly greater than in the other two groups, despite the increased porosity. We speculate the reason to be that porosity increased near the endocortical surface, where its mechanical effect is small. This increase was more than offset by apposition of new bone on the periosteal surface. These data suggest that (1) PTH increases cortical porosity in a dose-dependent manner, primarily near endocortical surfaces; (2) because of this nonhomogeneous distribution, the mechanical effect of increased porosity is small; (3) the increased cortical porosity associated with PTH treatment is more than offset by periosteal apposition of new bone, causing an overall increase in the bending rigidity of cortical bone; and (4) these changes cannot be accurately evaluated using noninvasive methods of bone densitometry, which cannot account for the location of bone gain and bone loss.
引用
收藏
页码:456 / 460
页数:5
相关论文
共 29 条
[1]  
[Anonymous], J BONE MINER RES
[2]   RESPONSE OF CORTICAL BONE TO ANTIRESORPTIVE AGENTS AND PARATHYROID-HORMONE IN AGED OVARIECTOMIZED RATS [J].
BAUMANN, BD ;
WRONSKI, TJ .
BONE, 1995, 16 (02) :247-253
[3]  
Boyce RW, 1996, J BONE MINER RES, V11, P600
[4]  
EJERSTED C, 1993, J BONE MINER RES, V8, P1097
[5]   Bisphosphonate maintains parathyroid hormone (1-34)-induced cortical bone mass and mechanical strength in old rats [J].
Ejersted, C ;
Oxlund, H ;
Andreassen, TT .
CALCIFIED TISSUE INTERNATIONAL, 1998, 62 (04) :316-322
[6]   INCREASED TRABECULAR BONE MASS IN RATS TREATED WITH HUMAN SYNTHETIC PARATHYROID-HORMONE [J].
GUNNESSHEY, M ;
HOCK, JM .
METABOLIC BONE DISEASE & RELATED RESEARCH, 1984, 5 (04) :177-181
[7]   THE RELATIONSHIP BETWEEN CHANGES IN FEMORAL BONE-DENSITY AND CALCIUM BALANCE IN PATIENTS WITH INVOLUTIONAL OSTEOPOROSIS TREATED WITH HUMAN PARATHYROID-HORMONE FRAGMENT (HPTH-1-34) [J].
HESP, R ;
HULME, P ;
WILLIAMS, D ;
REEVE, J .
METABOLIC BONE DISEASE & RELATED RESEARCH, 1981, 2 (05) :331-334
[8]   Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits [J].
Hirano, T ;
Burr, DB ;
Turner, CH ;
Sato, M ;
Cain, RL ;
Hock, JM .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (04) :536-545
[9]   A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis [J].
Hodsman, AB ;
Fraher, LJ ;
Watson, PH ;
Ostbye, T ;
Stitt, LW ;
Adachi, JD ;
Taves, DH ;
Drost, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :620-628
[10]   BONE DENSITOMETRIC AND HISTOMORPHOMETRIC RESPONSES TO SEQUENTIAL HUMAN PARATHYROID-HORMONE (1-38) AND SALMON-CALCITONIN IN OSTEOPOROTIC PATIENTS [J].
HODSMAN, AB ;
STEER, BM ;
FRAHER, LJ ;
DROST, DJ .
BONE AND MINERAL, 1991, 14 (01) :67-83